Sanofi Research

Sanofi Research, Avenue de Bejar, B-1120 Brussels, Belgium Dr W. Kitching... 

Personnel at the Sanofi Research Division of Philadelphia recently developed an expert system for the formulation of hard gelatin capsules based on specific preformulation data of the active ingredient. Using Formulogic, the system generates one first-pass clinical capsule formulation with as many subsequent... 

Capsules Sanofi Research Division Capsugel/University of London University of Heidelberg (GSH) PFES C C/SMALLTALK Bateman et al. (1996) Lai et al. (1995, 1996)... 

Gachon R, Sanofi-Research. Internal Scientific and Technical Report. 

Dr S. Nicholas Kilenyi Sanofi Research, Avenue de Bejar 1, Bruxelles, B-1120, Belgium... 

Sanofi-Synthelabo researchers discovered pyrazole 53 and analogs to have potent Cannabinoid receptor-1 (CB-1) antagonist/inverse agonist activity and have progressed 53 into development for treatment of obesity and alcohol dependence. The synthesis of 53 was accomplished by heating the diketone sodium salt 51 with the aryl hydrazine hydrochloride in acetic acid to provide the intermediate 52, which was further derivatized... 

Achour, Z., Laidboeur, T., Gien, O., Musolino, A., Bon, X., Grimaud, B. (2005) Sanofi-Synthelabo Chemical Development and the Development of an Electronic Laboratory Notebook. Organic Process Research Development, 8, 983-997. 

The search for an effective non-peptide oxytocin antagonist has become a major goal of a number of pharmaceutical companies because of the poor pharmacokinetic properties and especially the lack of oral bioavailability associated with peptidic antagonists. Early research in this field was dominated by Merck, but in recent years significant research efforts at GlaxoSmithKline and Serono have been published. A number of other companies, notably Sanofi-Aventis, Yamanouchi and Wyeth, have had a major presence in vasopressin receptor research and oxytocin is frequently included in patent claims for the molecules. Occasionally, oxytocin-selective compounds have been reported, usually derived by adaptation of the vasopressin antagonist template. 

J. M. Herbert carried out his PhD research with associate professor P.D. Woodgate and Dr. W.A. Denny at the University of Auckland, into the synthesis and reactions of perimidine derivatives. He then carried out postdoctoral research with Dr. R.J.K. Taylor at the University of East Anglia on the reactions of pyrylium salts, before moving into Industry. He is presently a team leader in the Isotope Chemistry and Metabolite Synthesis Department of sanofi-aventis in Alnwick, UK. 

Discovery Analytics, Discovery Research, Sanofi-Aventis, Milano, Italy... 

Crystallization-induced asymmetric transformation has already been described by Leuchs in 1913 during the resolution of 2-(2-carboxybenzyl)-l-indanone with brucine.34 In this case spontaneous racemization occurred. More recently researchers at Sanofi observed spontaneous racemization during the resolution of 3-cyano-3-(3,4-dichlorophenyl)propionic acid (7), most likely as a result of the basic resolving agent [>-(-)-N-1 n etli y I g I near nine [d-(-)-MGA] (8) (Scheme 7.6).35 The enantiopure cyano acid, obtained in 91% overall yield, is subsequently reduced to (+)-4-amino-3-(3,4-dichlorophenyl)-l-butanol (9), a key intermediate in the phase 2 synthesis of tachykinin antagonists. 

Several companies including Merck,23,24 Sanofi-Aventis,26,27 and Proctor Gamble,28 published papers that described research programs that targeted selective Kvl.5 blockers. In 2003 Cardiome Pharmaceuticals submitted the first of several patents applications that describe tra s-cyclohexylamine alkyl ethers (including 8, 9, and 1) and claimed that these compounds showed specificity for inhibition of atrially expressed potassium... 

Research Triangle Institute Rodaris Pharmaceuticals Limited Roche Palo Alto LLC Sanofi-Aventis Deutschland GmbH SB Corporation... 

Sanofi-Synthelabo Research, Chilly Mazarin, France... 

Gareth A. Lewis / Sanofi-Synthelabo Research, Chilly Mazarin, Erance Luk Chiu Li / HPD Advanced Drug Delivery, Abbott Park, Illinois, U.S.A. 

Khawla Abu-Izza Sanofi-Synthelabo Research Malvern, Pennsylvania... 

Veronique Thybaud, Ph.D. Scientific Advisor, Disposition-Safety and Animal Research, Preclinical Safety, Sanofi Aventis, Vitry sur Seine, France... 

Sanofi-Synthelabo Research Alnwick Research Centre Alnwick, Northumberland, U.K. 

---